BR112014005730A2 - método de tratar carcinoma mucoepidermóide - Google Patents

método de tratar carcinoma mucoepidermóide

Info

Publication number
BR112014005730A2
BR112014005730A2 BR112014005730A BR112014005730A BR112014005730A2 BR 112014005730 A2 BR112014005730 A2 BR 112014005730A2 BR 112014005730 A BR112014005730 A BR 112014005730A BR 112014005730 A BR112014005730 A BR 112014005730A BR 112014005730 A2 BR112014005730 A2 BR 112014005730A2
Authority
BR
Brazil
Prior art keywords
mucoepidermoid carcinoma
treating
proliferation
development
formula
Prior art date
Application number
BR112014005730A
Other languages
English (en)
Inventor
D Griffin James
Chen Jie
Wu Lizi
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BR112014005730A2 publication Critical patent/BR112014005730A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1/1 resumo “método de tratar carcinoma mucoepidermóide” imidazoquinolinas, como apresentado na fórmula (i), são úteis para inibir o desenvolvimento ou proliferação de células de carcinoma mucoepidermóide. os tratamentos terapêuticos e profiláticos fornecidos por esta invenção são praticados pela administração, a um paciente em necessidade deste, de uma quantidade de um composto da fórmula (i) que é eficaz para inibir o desenvolvimento ou proliferação das células de carcinoma mucoepidermóide.
BR112014005730A 2011-09-30 2012-09-27 método de tratar carcinoma mucoepidermóide BR112014005730A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161541758P 2011-09-30 2011-09-30
US201261660377P 2012-06-15 2012-06-15
PCT/US2012/057480 WO2013049300A1 (en) 2011-09-30 2012-09-27 Method of treating mucoepidermoid carcinoma

Publications (1)

Publication Number Publication Date
BR112014005730A2 true BR112014005730A2 (pt) 2017-03-28

Family

ID=47016842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005730A BR112014005730A2 (pt) 2011-09-30 2012-09-27 método de tratar carcinoma mucoepidermóide

Country Status (12)

Country Link
US (1) US20140243396A1 (pt)
EP (1) EP2760445A1 (pt)
JP (1) JP2014532057A (pt)
KR (1) KR20140069038A (pt)
CN (1) CN103906515A (pt)
AU (1) AU2012316020A1 (pt)
BR (1) BR112014005730A2 (pt)
CA (1) CA2848065A1 (pt)
EA (1) EA201490725A1 (pt)
IN (1) IN2014CN02315A (pt)
MX (1) MX2014003873A (pt)
WO (1) WO2013049300A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847491A (zh) 2015-05-20 2018-03-27 诺华公司 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
AU2017363970A1 (en) 2016-11-23 2019-06-20 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
US20200362303A1 (en) * 2017-11-30 2020-11-19 Kyoto University Maintenance-and-amplification method and differentiation induction method for primordial germ cells/primordial germ cell-like cells
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604629A1 (en) 2005-04-11 2006-10-19 The Trustees Of Columbia University In The City Of New York Methods for treating mild cognitive impairment
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN106045993A (zh) * 2006-11-20 2016-10-26 诺华股份有限公司 化合物的盐和晶型
WO2009052467A1 (en) * 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
US20090192220A1 (en) * 2007-11-19 2009-07-30 Ore Pharmaceuticals Inc. Treatment for solid tumors
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
WO2012068487A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status

Also Published As

Publication number Publication date
MX2014003873A (es) 2014-05-28
KR20140069038A (ko) 2014-06-09
IN2014CN02315A (pt) 2015-06-19
CN103906515A (zh) 2014-07-02
WO2013049300A1 (en) 2013-04-04
CA2848065A1 (en) 2013-04-04
AU2012316020A1 (en) 2013-05-09
JP2014532057A (ja) 2014-12-04
EA201490725A1 (ru) 2014-11-28
US20140243396A1 (en) 2014-08-28
EP2760445A1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
BR112013020159A2 (pt) método para inibir células tumorais de hamartoma
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112014026703A2 (pt) inibidores de dna-pk
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR112012023021A2 (pt) compostos de indazol e seus usos
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112012024678A2 (pt) composto, composição farmacêutica, e, métodos para tratar e para previnir uma doença ou distúrbio
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112014028042A2 (pt) inibidores de nampt
BR112014019399A2 (pt) métodos de tratamento da fibrose
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112014011641A2 (pt) composto; composição; uso de um composto; método para tratar pelo menos uma doença, distúrbio ou condição selecionada de obesidade, sobrepeso ou distribuição de gordura anormal e condições ou doenças associadas com os mesmos em um sujeito em necessidade do mesmo; método para remodelar tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; método para tratar uma doença, distúrbio ou condição associada com ou se beneficiando da remodelação de tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; e método para reduzir o tecido adiposo branco (wat) em um sujeito em necessidade do mesmo
GT201700220A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]